RxDoctor Payments Data

Leigh Powers

Psychiatric/Mental Health · Niceville, FLNPI 1831280403

Payments from drug & device makers

$1,764in general payments, 2019–2025

Across 94 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$311
  • Idorsia Pharmaceuticals US Inc$293
  • AbbVie$240
  • Lundbeck LLC$224
  • Takeda Pharmaceuticals U.S.A., Inc.$100
  • Johnson & Johnson$99
  • plus $497 from 15 others

What the payments were for

  • Food & beverage$1,764100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,764 in reported general payments places this provider in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$38,604
Medicare patients
80
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate13$22,276
VraylarCariprazine Hcl12$20,116
QuviviqDaridorexant Hcl11$5,574
Vilazodone Hcl29$2,526
Venlafaxine Hcl ErVenlafaxine Hcl37$1,812
Clozapine12$1,221
Divalproex Sodium13$1,010
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine22$1,001
Quetiapine Fumarate48$783
Lamotrigine37$737
Bupropion XlBupropion Hcl21$685
Duloxetine Hcl16$633
Gabapentin28$454
Trazodone Hcl51$448
Clonazepam53$446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$72$22,27613 claims
AbbVieVraylar$240$20,11612 claims
Idorsia Pharmaceuticals US IncQuviviq$293$5,57411 claims
Almatica Pharma LLCSertraline Hcl$37$19630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Niceville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →